Syngen Biotech Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	283.17	341.93	366.89	246.05	314.8	423.42
Cash & Short-Term Investments	283.17	341.93	366.89	246.05	314.8	423.42
Cash Growth	24.03%	-6.80%	49.11%	-21.84%	-25.65%	-18.48%
Accounts Receivable	496.39	422.56	387.8	472.06	388.16	298.71
Other Receivables	0	0	0	0	0	-
Receivables	496.39	422.56	387.8	472.06	388.16	298.71
Inventory	350.32	345.62	348.99	369.35	291.96	259.78
Prepaid Expenses	33.23	44.93	28.77	25.42	23.17	34.92
Total Current Assets	1,163	1,155	1,132	1,113	1,018	1,017
Property, Plant & Equipment	1,475	1,518	1,526	1,543	1,035	1,035
Long-Term Investments	327.82	324.34	331.74	313.75	293.55	2.7
Other Intangible Assets	36.96	27.57	24.13	22.96	23.42	27.32
Long-Term Deferred Tax Assets	17.56	18.86	17.44	16.21	12.32	10.39
Other Long-Term Assets	49.17	38.4	73.21	58.7	28.23	28.94
Total Assets	3,072	3,085	3,106	3,071	2,416	2,127
Accounts Payable	247.87	255.87	226.47	248.45	236.86	140.59
Accrued Expenses	78.67	78.84	72.8	79.89	64.72	3.94
Short-Term Debt	40	-	80	230	-	50
Current Portion of Long-Term Debt	59.03	59.03	59.03	-	-	-
Current Portion of Leases	15.15	14.71	13.38	14.85	13.7	14.11
Current Income Taxes Payable	25.85	35.18	62.06	76.99	58.39	28.12
Current Unearned Revenue	33.31	24.83	20.04	6.73	6.55	1.97
Other Current Liabilities	64.85	51.7	50.81	62.56	38.4	73.27
Total Current Liabilities	564.72	520.16	584.58	719.47	418.61	312
Long-Term Debt	19.68	163.95	222.97	182	50	-
Long-Term Leases	149.88	160.25	163.1	173.93	172.39	186.17
Long-Term Deferred Tax Liabilities	3.24	4.17	3.98	3.93	3.16	2.58
Total Liabilities	737.51	848.52	974.63	1,079	644.16	500.74
Common Stock	271.01	271.01	271.01	271.01	271.01	271.01
Additional Paid-In Capital	618.36	618.24	618.2	618.06	612.83	610.54
Retained Earnings	1,442	1,344	1,243	1,103	887.88	744.67
Comprehensive Income & Other	2.41	2.73	-0.26	-0.07	-0.36	-0.12
Shareholders' Equity	2,334	2,236	2,132	1,992	1,771	1,626
Total Liabilities & Equity	3,072	3,085	3,106	3,071	2,416	2,127
Total Debt	283.73	397.93	538.49	600.78	236.08	250.28
Net Cash (Debt)	-0.56	-56	-171.6	-354.73	78.72	173.14
Net Cash Growth	-	-	-	-	-54.53%	-52.69%
Net Cash Per Share	-0.02	-2.06	-6.33	-13.07	2.90	6.38
Filing Date Shares Outstanding	27.1	27.1	27.1	27.1	27.1	27.1
Total Common Shares Outstanding	27.1	27.1	27.1	27.1	27.1	27.1
Working Capital	598.39	634.89	547.87	393.41	599.48	704.84
Book Value Per Share	86.13	82.51	78.66	73.49	65.36	60.00
Tangible Book Value	2,297	2,209	2,107	1,969	1,748	1,599
Tangible Book Value Per Share	84.76	81.49	77.76	72.64	64.50	58.99
Land	251	251	251	251	-	-
Buildings	818.55	729.7	717.09	702.28	532.98	529.5
Machinery	1,042	1,022	871.44	841.51	693.37	656.19
Construction In Progress	3.49	74.67	146.33	114.01	111.97	79.98

Source: S&P Global Market Intelligence. Standard template. Financial Sources.